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Introduction
Twenty-five million people to date have died from AIDS. An estimated thirty-
nine million people worldwide were living with HIV at the end of 2005.
Twenty-five million of these live in Sub-Saharan Africa. Inhabited by just over
twelve percent of the world’s population, Africa is estimated to have more than
sixty four percent of the AIDS-infected population1. Of these twenty-five million
people infected with the HIV, only one million have access to antiretroviral drugs
(ARVs). Unlike in the West where many people can afford to buy these life-saving
drugs, many Africans find ARVs too expensive to buy. The challenge then is to
make these drugs accessible to those that desperately need them as their current
exorbitant prices condemn many living with the virus to premature deaths. The
question that can be asked is: who is responsible to make the prices of these ARVs
affordable to those living with HIV/AIDS in Africa? This paper argues that the
pharmaceutical companies, presumably as moral agents, are largely responsible
to make the prices of these ARVs affordable to those infected. Pharmaceutical
companies have a moral duty not to use humans as a means to their ends.
Immanuel Kant in his espousal of his moral theory asserts that in whatever we do
we must always treat humanity as an end in itself. Treating humanity in persons
has both positive as well as negative senses. It may be argued, therefore, that by
pricing the ARVs highly to generate huge profits, the pharmaceutical companies
are treating humanity as a means to their goal of profit maximization. Unless the
pharmaceutical companies treat humanity as an end in itself, many lives will be
condemned to premature deaths and the battle against AIDS will never be won in
Africa. 
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HIV/AIDS treatment and pricing of ARVs
HIV stands for human immunodeficiency virus. This is the virus that causes a
disease called AIDS. The term AIDS means acquired immunodeficiency
syndrome and is a collection of symptoms and resulting infections resulting from
the specific damage to the immune system caused by HIV.  It is the most advanced
stage of the HIV infection. It is transmitted through direct contact with a bodily
fluid containing HIV. At the moment there is no cure or vaccine for AIDS. People
can know if they have HIV and AIDS only when they have their blood tested.
However, a positive HIV result does not mean that a person has AIDS. Actually
it may take years for full blown AIDS to manifest. 
According to UNAIDS/WHO 2006 Report on the global AIDS epidemic, Sub-
Saharan Africa is the worst-affected by HIV and AIDS than any other region of
the world. An estimated 24.5 million people were living with HIV at the end of
2005 and approximately 2.7 million additional people were infected with HIV
during that year. In 2005 the AIDS pandemic claimed an estimated 2 million
people in the Sub-Saharan Africa. More than twelve million children have been
orphaned by AIDS. According to the same report, the figures of people living
with HIV in the world’s regions as of December 2005 were as follows: Middle
East and North Africa 460,000; South and South-East Asia 7.8 million; East Asia
750,000; Oceania 81,000; Latin America 1.7 million; Caribbean 250,000; Eastern
Europe and Central Asia 1.7 million; Western and Central Europe 740,000; and
North America 1.4 million. 
The introduction of antiretroviral drugs has dramatically reduced mortality from
AIDS in wealthy countries, but has not significantly altered the course of the
disease in Africa. Currently for most of those with AIDS in Africa ARVs are still
unaffordable. Of the twenty-five million people infected with the HIV in Africa
only one million have access to antiretroviral therapy. However, this was far
below the target set by WHO and UNAIDS whereby three million people were
to have access to HIV treatment by the year 2005 through an initiative dubbed 
'3 x 5' programme. The barriers are partly social and logistical, but the
overwhelming barrier is cost2. This agrees with what Carmen Pérez-Casas
observes in the Bulletin of Experimental Treatment for AIDS (2001) that many
factors affect access to these medicines, but the most significant barrier to access
is the price of the drugs. However, access to the life prolonging drugs is being
recognised as a key factor to improving the quality of life of those infected. The
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key factor in the expense of ARVs is their patent status, which allows drug
companies to recoup research costs and turn a profit, enabling the development
of new drugs. In view of this, some international aid organisations such as VSO,
Oxfam and Médecines Sans Frontières have questioned whether the revenues
generated by ARVs really tally with research costs. In contrast, in some African
countries, ARVs are available for under US$140 per person per year. These are
supplied by drug manufacturers in Brazil, India, Thailand, and China who have
manufactured generic copies of patented ARV drugs produced in Western
countries. However, the prices for these ARVs are still unaffordable to many
Africans who live on less than a dollar a day. This is one of the major reasons cited
for treatment interruptions. Chinua Akukwe3 argues that more than 40% of
Africans live on 65 cents a day and that they cannot afford the high cost of ARVs.
It is therefore unlikely that African governments can ever afford the expensive
drugs.
ARVs are expensive. Of course, most people in Western countries due to their
sound economies can afford to buy these drugs. In Western countries, ARV
treatment costs between US $10,000 and US $15,000 per year per person.
Generally, pharmaceuticals find Africa to be unlucrative market for the ARVs. It
can, therefore, be argued that most drug companies are not making huge profits
out of the antiretroviral drugs in Africa. In trying to answer the question: ‘What
is the best negotiable price for the ARVs and how will this change over time?’
Stephen S. Forsythe argues that there are two major reasons why pharmaceutical
companies are afraid to lower down the prices of the ARVs4. First, while they
recognise that the retail price for ARVs is expensive in developed countries
(between US$ 10,000 and $15,000 per person per year), they are also concerned
that offering ARVs for a discount in developing countries could create arbitrage
opportunities that could significantly reduce their profit levels (purchasing ARVs
at a lower price in developing countries and reselling them in developed
countries). Second, they are also concerned that eventually there will be demands
by health insurance providers and activists in developed countries to reduce their
prices to levels in developing countries. As can be noted, pharmaceutical
companies would want to make as much profits out of the ARVs at the expense
of the many millions living with AIDS. However, little information is available




Humanity as an end in itself and the pricing of ARVs
Immanuel Kant (1724-1804) made important contributions to all the major fields
of philosophy and is considered one of the most influential philosophers in
history. He wrote three important books in moral philosophy: Groundwork of the
Metaphysics of Morals (1785), Critique of Practical Reason (1788), and The
Metaphysics of Morals (1797). Kant’s moral theory attempts to make sense of
the ordinary, commonsense idea of duty5. At the heart of Kant’s moral philosophy
is this supreme principle of morality that he calls the categorical imperative. The
categorical imperative has three formulations. The most famous two are 1) Act
only according to that maxim whereby you can at the same time will that it should
become a universal law; and 2) treat humanity in oneself and others always as an
end and never merely as a means.According to Kant, the various formulations of
the categorical imperative are all different ways of expressing the very same
principle, which is deeply rooted in the connection between reason, the moral
law and human freedom. In this essay I am articulating that Kant’s second
formulation condemns the approach taken by pharmaceutical companies to charge
ARVs exorbitantly to make profits at the expense of human lives in Africa. Thus,
pharmaceutical companies are being unethical and exploitative in their ARV
business in Africa because they are using man as a means to their ends.
In his second formulation of the categorical imperative, Kant asserts that we treat
humanity in oneself and others always as an end and never merely as a means.
Thus, Kant argues, 
“humanity as an objective end is one such that in its place one can put no
other end to which (it) should serve simply as a means...”6
One interpretation of the above is that a person can, and too often does, treat
humanity in his own person merely as a means; for this means , among other
things, being willing to trade or sacrifice his rational capacities for something of
value merely because he happens to want it.7 Thus Kant’s second formulation
condemns sacrifice of life for what has mere price, i.e, fame or money (profits).
Kant argues that humanity in persons has an unconditional and incompatible
worth. Humanity has dignity and this dignity has intrinsic value. Human dignity
is an “incomparable” worth, “exalted above all price,” and “admits of no
equivalents.”8 This dignity is what we all need to respect whenever we act because
it has precedence over relative and arbitrary ends. 
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From the categorical imperative we can derive all other duties and these can be
organized into a system. In light of this, the two most general duties that we have
are (1) the duty of self-perfection and (2) the duty to promote the happiness of
others.9 From these general duties we can derive further, more specific duties.
For instance, in promoting the happiness of others we are required to develop
attitudes of beneficence, gratitude, sympathy and respect for others as ends in
themselves. Thus ‘respect’ in a Kantian sense would imply both negative and
positive duties since passive avoidance of evil and the active pursuit of good are
simply two sides of the same moral coin. Respect for the humanity of others
implies a positive duty since one has to take account of the ends of others in one’s
own plans. Kant’s moral theory prevents moral agents from using man as a means
to any particular end.
Pharmaceutical companies as moral agents have moral responsibilities. A question
that should be answered then is: what moral responsibilities do pharmaceutical
companies have? Kant would argue that companies, besides profit-making, must
see to it that the welfare and dignity of persons is respected. In other words,
companies must see the necessity of equal balance among the following business
considerations: profit, consumer satisfaction, and societal well-being. There are
certain expectations that must be met specifically by pharmaceutical companies.
Thus Kant would insist that respect for the intrinsic worth of other people must
take precedence in business. This may mean that drug companies need to make
the drugs affordable to those that need them. Societies expect drug companies to
function ethically through acts of beneficence, benevolence, sympathy, and
respect for others. This is a requirement in Kant’s moral theory.
Many millions of Africans are dying because they cannot afford to buy ARVs.
This is happening when the drug companies are busy accumulating huge profits.
Carmen Pérez-Casas writes:
Whatever the true investment of the pharmaceutical industry in researching
and developing antiretrovirals, these drugs have earned the companies
consistent revenue. Between 1997 and 1999, Glaxo Wellcome's sales for AZT,
3TC, and Combivir totalled more than $3.8 billion. Bristol-Myers Squibb
sold more than $2 billion worth of d4T and ddI over the same period.10
Looking at the revenues above, it can be argued that drug companies are the most
profitable industry in the world. But these companies have the power to save lives
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by making the life-saving drugs affordable. Kant would argue that they are using
man as means to their ends-merely generating more profits. Exploitation can be
defined as occurring when one person gains by using a character of another person
to his/her own advantage.11 Exploitation, then, would include pharmaceutical
companies raising a huge profit out of the AIDS pandemic, taking advantage of
people’s ill health, by overpricing the ARVs. In this the patients (consumers) are
harmed and taken advantage of, and the drug companies are profiting off the
desperation of the patients. In other words, the companies’ gain is disproportionate
when compared with the exploited.  
Pharmaceutical companies have a duty to save lives because they have the
capacity to do so, and can do so with little effort. David Resnik argues that
pharmaceutical companies have the moral obligation to manufacture affordable
drugs for developing countries and to make these accessible to promote the
welfare of humankind.12 Others have also argued that pharmaceutical companies
have special obligations to the suffering in developing countries because of their
nature. They have the expertise that others lack, and because they make their
living or profit from health-related activities, this gives them much more
obligation than other companies.13 The argument here is that pharmaceutical
companies can save lives of those suffering with little effort. It is clear then that
the obligations that drug companies have to the people relate to eradicating
suffering and improving the quality of lives of the sick and not using them as a
means.
Recent studies have shown that in countries which had an HIV epidemic where
the prices of ARVs were reduced as a result of efforts by the national governments
to give these drugs at affordable prices, mortality and morbidity rates have
tremendously been reduced. A case in point is Brazil. William Flanagan and Gail
Whiteman in their paper “AIDS is Not a Business,” write: 
“At the end of the 1990s, Brazil was faced with a potentially explosive
HIV/AIDS epidemic. Through an innovative and multifaceted campaign, and
despite initial resistance from multinational pharmaceutical companies, the
government of Brazil was able to negotiate price reductions for HIV
medications and develop local production capacity, thereby averting a public
disaster.”14
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This simply supports the point that reducing the AIDS drugs is the surest way of
dealing with the HIV and AIDS scourge in Africa and requires concerted efforts
from all parties involved in the fight against HIV and AIDS.
Corporate social responsibility and pharmaceutical companies
The concept of corporate social responsibility (CSR) has generated a lot of debate
in business ethics in recent years. There are varied definitions for the concept of
corporate social responsibility. Archie B. Carroll defines CSR by saying that:
The social responsibility of business encompasses the economic, legal,
ethical, and discretionary (philanthropic) expectations that society has of
organizations at a given point in time.15
In other words, a socially responsible corporation should strive to make profits,
obey the law, be ethical and be a good corporate citizen. This is in sharp contrast
to Milton Friedman’s arguments that corporations have no social responsibility
but to maximize profits.16 This then means that profitability and responsibility go
hand in hand. In globalised economy, the interests of stakeholders of corporations
need to be taken seriously. In this way the concept of corporate social
responsibility supports Kant’s moral theory. Pharmaceutical companies need to
help to reduce the suffering and improve the health and quality of life of people
around the world.  HIV and AIDS being a socio-economic problem needs urgent
attention of the pharmaceutical companies. They can deal with it either by
donating ARVs or making them affordable. The latter seems practical than the
former since pharmaceuticals need to recoup production costs of the ARVs.  It is
morally problematic to price ARVs highly to a huge population that is dying of
HIV and AIDS when something can be done to arrest the situation.
Pharmaceutical companies have a special moral duty in this case to save lives of
those impoverished and living with the virus in developing world because they
produce the life-saving drugs.
Who’s in the business of saving lives?
So far I have consistently argued that pharmaceutical companies have special
moral obligations towards society. These obligations are based on Kant’s moral
theory and the notion of corporate social responsibility (CSR). However, others
have argued to the contrary. Some take an extreme position to deny that
corporations in general and pharmaceuticals in particular are moral agents and
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that it is unreasonable to argue that they have moral responsibility to the society.
Still others insist that pharmaceutical companies do not have any special moral
obligations to the society but that their social responsibility is the same as that of
any other corporations. Pepe Lee Chang in his paper, “Who’s in the Business of
Saving Lives?” thinks all companies have same obligations and he argues: 
“...there is no distinction with respect to responsibilities, between
pharmaceutical companies that produce life-saving drugs and companies that
produce other products.”17
Lee observes that the duty bestowed on a company to save lives derived from the
ability to do so, and to do so with little effort is misplaced. This means that to hold
pharmaceutical companies especially responsible for saving lives in third world
countries is unjustified. This is so because drugs are not the only things that save
lives. Money can also be used to save lives. Money can be used to purchase
needed supplies, drugs, provide doctors, etc. And this can be done by all
corporations that are allowed to reach and maintain a reasonable profit margin and
they can do that with little effort. 
An extension of Lee’s argument would be what Thomas W. Poggle echoes in his
paper titled “Human Rights and Global Health: A Research Program.” Poggle
offers a plausible explanation when he argues that reducing the prices for drugs
in Africa is a responsibility not only of drug companies but also of other parties
like African governments, affluent citizens and governments, international
organizations, such as the World Trade Organization and the World Health
Organization, academics, and non-governmental organizations. He observes that
pharmaceuticals spend huge sums of money to produce and market the life-saving
medications, and that to demand a reduction in the prices of these drugs is asking
too much from them. Companies need profits for their sustainability. The one
important way to lower the prices of drugs in poor countries is by rewarding
pharmaceuticals on the basis of the impact that their new drugs have on the global
disease burden. This can be achieved through what he calls “public-good
strategy”. This strategy can be implemented by; a) allowing all pharmaceutical
companies to have access to discoveries of new essential drugs free of charge, and
b) allowing all inventor firms to be entitled to take a multiyear patent on any
essential medicines they invent and that during the life of the patent they should
be rewarded, out of public funds, in proportion to the impact of their invention on
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the global disease burden.18 This means that once the drug companies agree to
these global institutional reforms then they would have the incentives to work
together to bring drug prices down worldwide close to their marginal cost of
production and the drugs would be accessible and affordable even to the poor
countries.  These initiatives will also make inventor firms to encourage and
support efforts by cheap generic producers to copy their drugs. This would
certainly promote the interests of inventor firms, patients and those of generic
drug producers. Eventually the drugs would be cheaper to patients but at the same
time drug companies will sustain their businesses. Inevitably most premature
deaths will be avoided. This can only be achieved if all parties play their roles to
bring the prices of ARVs down. This should be a shared responsibility. After all,
responsibilities of human persons are quite different from those of corporations.
Corporations are considered as ‘artificial persons’. Responsibilities of human
persons go beyond those of ‘artificial persons’, i.e, pharmaceuticals. Expanding
access to antiretroviral treatment is a global endeavour. However, the challenge
for pharmaceuticals is to take a lead in this project. As to how pharmaceuticals and
other parties can work out this and implement it is beyond the scope of this essay
and there is need for further research in that area. Making ARVs affordable would
be considering humanity as an end in itself and not a means.
Conclusion
AIDS pandemic in Africa needs urgent attention. With twenty-five million people
living with HIV in Africa, ARVs must be made available at affordable prices.
Many Africans cannot afford the patented as well as the generic ARVs.  The
current prices are exorbitant and condemn many poor people to premature deaths.
There are many factors affecting inaccessibility to these essential life-saving
drugs, but the most significant barrier to access is the price of the drugs. Pricing
the life-saving drugs highly to people who are too poor to afford them is morally
problematic. Pharmaceutical companies being manufactures and marketers of
these life-saving drugs have a major role to play in making the prices of these
drugs affordable. They have special obligations which when performed will save
the lives of the many impoverished AIDS patients.  Drug companies hold the key
to the reduction in prices of these ARVs. Of course, they cannot do it alone. Along
with other parties like WTO, WHO, UNAIDS, national governments, and NGOs
modalities can be worked out on how the ARVs can be made available to the poor
at affordable prices. This would be what Kant means by respecting humanity and
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taking humanity as an end in itself. This is the major social responsibility that
pharmaceuticals have in the 21st Century. 
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